Liver cancer stem cell therapy

Drug Profile

Liver cancer stem cell therapy

Alternative Names: Hepatocellular carcinoma stem cell therapy - NeoStem Oncology; Tumor stem cell specific dendritic cell therapy - Cellular Biomedicine Group; Tumor stem cell specific dendritic cell vaccine - Cellular Biomedicine Group; Tumour stem cell specific dendritic cell therapy - Cellular Biomedicine Group; Tumour stem cell specific dendritic cell vaccine - Cellular Biomedicine Group

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer Cellular Biomedicine Group
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatocellular carcinoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatocellular carcinoma in China (SC, Injection)
  • 11 Sep 2014 NeoStem Oncology licenses patents covering methods for use of apoptotic cells to deliver antigen to dendritic cells from Rockefeller University
  • 29 May 2014 DC-TC immunotherapy licensed to Cellular Biomedicines in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top